Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
114 hedge funds and large institutions have $421M invested in Taro Pharmaceutical Industries Ltd. in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 31 reducing their positions, and 16 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
5% more funds holding
Funds holding: 109 → 114 (+5)
3% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 31
16% less capital invested
Capital invested by funds: $500M → $421M (-$78.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Globeflex Capital
San Diego,
California
|
+$7.84M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.92M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.86M |
| 4 |
Renaissance Technologies
New York
|
+$4.76M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$16.7M |
| 2 |
FL
Fort LP
Chevy Chase,
Maryland
|
-$5.76M |
| 3 |
Millennium Management
New York
|
-$5.49M |
| 4 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
-$3.4M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.81M |
TARO Hedge Fund Activity: Q3 2018 in Review
114 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2018, worth a combined $421M — down 16% from $500M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TARO positions and 16 closed out — a net gain of 5 holders — while 32 added to existing stakes and 31 trimmed.
The largest buyer was Globeflex Capital, opening a new position worth an estimated $7.84M. The largest seller was Matthews International Capital Management, exiting entirely with an estimated $16.7M sold.
- 114 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2018, up from 109 in Q2 2018.
- Funds reported $421M of Taro Pharmaceutical Industries Ltd. stock for Q3 2018, down 16% quarter-over-quarter.
- 21 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2018 and 16 closed out, a net change of +5 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2018 was Globeflex Capital, an estimated $7.84M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2018 was Matthews International Capital Management, an estimated $16.7M sold.
Based on aggregated 13F filings for Q3 2018.